

Nomination Committee for Biovica for the 2018 Annual General Meeting

Uppsala, Sweden, 2018-04-23

In accordance with the decision of the Annual General Meeting of Biovica International AB on August 31st, 2017, the Nomination Committee shall consist of three members, representing the two shareholders with the highest number of shares willing to be included in the Nomination Committee, and the Chairman of the Board. The Nomination Committee then elects the chairman.

In accordance with the above guidelines, the Nomination Committee for the 2018 Annual General Meeting will consist of the following persons:

- Gunnar Rylander, Chairman of the Nomination Committee
- Leif Glantz
- Göran Brorsson, Chairman of the Board

The members of the Nomination Committee together represent approximately 33 percent of the shares and 47 percent of the votes in the company as of December 29, 2017.

The Nomination Committee has the task of working on proposals in the following questions to be submitted to the Annual General Meeting 2018 for decision:

- proposal for board members
- proposal for the Chairman of the Board
- proposal for board fees
- proposal for auditors and auditors fees
- proposal for the chairman of the Annual General Meeting
- proposals of guidelines for the Nomination Committee for the 2018 Annual General Meeting

Shareholders who wish to submit proposals to the company's nomination committee can do so by e-mail to goran.brorsson@gbrpartners.se or by letter to the address: Biovica International AB, Att: Nomination Committee, Dag Hammarskjölds väg 54B, 752 37 Uppsala

The Annual General Meeting of Biovica International AB will be held on 30 August 2018 in Uppsala.

More information:

Anders Rylander, CEO Biovica.

Phone: +46 (0)18 444 48 35,

E-mail: anders.rylander@biovica.com

In the event of contradictions or differences between the Swedish press release and this English translation of the Swedish press release, the Swedish text will be given priority.

About Biovica

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company's DiviTum[®] assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.

Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum[®] is CE-labeled and MPA-registered.

Read more: www.biovica.com